Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
Hepatitis C Virus (HCV) is a major etiological agent of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Fas-mediated apoptosis is the major cause of hepatocyte damage during liver disease. The present work was performed to study the fas system (Fas-FasL and soluble Fas) in chronic hepatitis C infection. Also, to correlate the degree of liver cell damage with the Fas system. The study was carried out on 45 patients positive for HCV RNA by nested RT-PCR in addition to 13 HCV negative control subjects. Wedge liver biopsies samples were obtained from patients and controls during abdominal operations for determination of cellular expression of Fas and Fas-L on hepatocytes and infiltrating lymphocytes respectively by flow cytometry. Histological activity index (HAI) was determined in chronic HCV patients. Also blood samples were taken from patients and controls for determination of sFas. There was statistically insignificant difference in Fas expression in hepatocytes of patients (P = 0.34) in comparison to control. Meanwhile, there was a statistically significant decrease in FasL expression in patients compared to control (P< 0.001) and statistically significant increase in soluble Fas in patients compared to control (P < 0.001). The HAI of liver fibrosis for all patients were within mild score with mean +/- SD 4 +/- 0.5. From this study, we could conclude that Fas system is one of the important pathways regulating the response to HCV infection. Increased serum sFas in HCV patients is accompanied by down-regulation of Fas/Fas-L expression resulting in inhibition of apoptosis in liver cells as a process for elimination of virus infected cells and this may ultimately leads to chronicity of the disease.
Zaki
Maysaa El Sayed
Mel S
Clinical Pathology Department, Mansoura University, Mansoura, Egypt. may_s65@hotmail.com
Auf
Fatma Abbas
FA
Ghawalby
Nabieh Anwar El
NA
Saddal
Nirmeen Mohamed El
NM
D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein / Q000096:biosynthesis*; D005260:Female; D005434:Flow Cytometry; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D019014:fas Receptor / Q000096:biosynthesis*
D053222:Fas Ligand Protein; D019014:fas Receptor